Ista touts data from Phase II age Xibrom studies

Ista Pharmaceuticals is touting positive data from two mid-stage studies of Xibrom, its once-daily formulation of the anti-inflammatory therapy. Tested on 500 patients who had undergone cataract surgery, Xibrom QB hit its primary endpoint of superiority to placebo for an absence of ocular inflammation 15 days after surgery. The secondary endpoint was superiority to placebo in eliminating ocular pain.

- take a look at this release from Ista

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.